Living with Wilson Ein Projekt von Betroffenen für Betroffene

← Zurück zu allen Antworten

My Wilson Disease Tests Are All Borderline — What Is the Next Step?

Borderline results are common in Wilson disease and do not mean the answer is no; the structured Leipzig scoring system and liver biopsy with copper quantification are the established next steps.

Borderline test results are frustrating precisely because they feel like non-answers. You came for clarity and left with ambiguity. But in Wilson disease, borderline results are actually expected — the disease sits on a spectrum, and the early or asymptomatic phase routinely produces values that fall between the normal and clearly abnormal range.1 The good news is that medicine has a structured approach for exactly this situation, and “borderline” is a starting point, not an endpoint.

Why Borderline Results Happen in Wilson Disease

The standard initial tests — serum ceruloplasmin, 24-hour urine copper, and liver enzymes — are useful screening tools, but none of them alone is a binary positive or negative. They each have ranges where normal and abnormal overlap:

  • Ceruloplasmin can be reduced in Wilson disease, but it is also reduced in severe liver disease from any cause, malnutrition, and nephrotic syndrome. Conversely, up to 15% of people with confirmed Wilson disease have a ceruloplasmin level in the normal range, particularly if they are heterozygous carriers or have a predominantly neurological presentation.2
  • 24-hour urine copper may be only mildly elevated in presymptomatic or early hepatic Wilson disease — the classic strongly elevated values tend to appear in more advanced cases or after a penicillamine challenge test.
  • Liver enzymes (ALT, AST) are often mildly elevated in Wilson disease but are non-specific; they fluctuate and can appear near-normal at any given point.
  • Kayser-Fleischer rings are absent in roughly 50% of people who present with liver-dominant (rather than neurological) Wilson disease.3

The bottom line: no single test definitively rules in or rules out Wilson disease. Diagnosis is made by combining multiple findings, not from any one result.

The Leipzig Scoring System

The Leipzig (or Ferenci) score is the structured diagnostic tool recommended by both AASLD 2022 and EASL guidelines for exactly this situation.14 It assigns points to a set of clinical and laboratory findings and produces a total score:

Score Interpretation
≥ 4 points Wilson disease highly probable — treat
2–3 points Possible Wilson disease — further testing needed
0–1 points Wilson disease unlikely

The components include:

Finding Points
Kayser-Fleischer rings present 2
Neuropsychiatric symptoms typical of WD 2
Ceruloplasmin severely reduced (<0.1 g/L) 2
Ceruloplasmin moderately reduced (0.1–0.2 g/L) 1
Coombs-negative haemolytic anaemia 1
Urine copper elevated (>2× upper limit of normal) 2
Urine copper 1–2× upper limit 1
Liver copper on biopsy >5× upper limit 2
Liver copper 0.8–4× upper limit 1
Rhodanine-positive hepatocytes on biopsy 1
Causative ATP7B mutations identified on both alleles 4
One ATP7B mutation found 1

If your initial tests land you in the 2–3 range, the guidelines are clear: more testing is indicated.1 The Leipzig system was specifically designed to manage borderline cases rather than forcing an immediate yes/no.

The Role of Liver Biopsy

When the Leipzig score is in the intermediate range and the diagnosis remains uncertain, liver biopsy with quantitative copper measurement is the next step most specialists will recommend.4 This is not the same as a routine liver biopsy for scarring. It specifically involves:

  1. Quantitative hepatic copper concentration — a direct measurement of how much copper is present in liver tissue. Values above 250 µg/g dry weight are strongly associated with Wilson disease; values above the upper limit of normal with a compatible clinical picture contribute significantly to the Leipzig score.
  2. Histological examination — the pathologist looks at the liver architecture, pattern of injury, and may use special stains (rhodanine or rubeanic acid) to visualise copper deposits, though these stains are not reliable at low copper levels.
  3. Biopsy for genetic material — some centres use the biopsy tissue for genetic analysis as well as copper measurement.

Liver biopsy carries a small but real procedural risk (bleeding, in rare cases). It is performed as a day procedure under imaging guidance at centres that do this routinely, and the risk is substantially lower than the risk of missing or delaying a treatable diagnosis.5

The Penicillamine Challenge Test

In children specifically, a penicillamine challenge test — giving a short course of the copper-chelating drug penicillamine and measuring the subsequent increase in urine copper excretion — can help distinguish Wilson disease from other causes of elevated urine copper.4 This test is used less often in adults and is not universally recommended, but it remains part of the toolkit in paediatric centres. Your specialist will advise whether it is appropriate for your child’s situation.

Extended Genetic Testing

If a standard genetic panel has already been done and returned negative or ambiguous results, full ATP7B gene sequencing — including analysis for large deletions and duplications — may resolve the picture. Identifying two pathogenic variants (one from each parent) gives 4 points on the Leipzig score, which on its own meets the threshold for diagnosis.1 See my genetic test came back negative for why a negative panel is not necessarily the final word.

What to Ask Your Doctor

When you go back to your specialist with borderline results, these questions will move the conversation forward:

  • “What is my Leipzig score based on all results so far, and what does it indicate?”
  • “Is liver biopsy with quantitative copper the next appropriate step?”
  • “Has full ATP7B sequencing been done, or only a targeted panel?”
  • “Is a penicillamine challenge test appropriate in my case?”
  • “Should I be referred to a hepatologist or metabolic liver disease specialist?”

If you have not yet been seen by a specialist — hepatologist, neurologist, or metabolic disease physician — a borderline picture is a strong reason to request that referral now. Rare disease diagnosis in a grey zone requires experience that a general physician may not have, and there is no shame in asking for specialist input.6

Living With Uncertainty While You Wait

It can take weeks to schedule a liver biopsy or get extended genetic results. During that period:

  • Continue the current monitoring plan — do not start self-treating with zinc or dietary copper restriction without medical guidance.
  • Keep a record of any new or changing symptoms (tremor, speech, mood, jaundice, fatigue) and report them.
  • The period of diagnostic uncertainty is stressful. The depression and anxiety page has resources for coping with the psychological weight of an uncertain diagnosis.
  • Ask your doctor explicitly: “While we wait for results, are there any warning signs that would mean I need to come in sooner?”

Borderline is uncomfortable, but it is manageable — and there are clear, evidence-based steps that lead out of it.

This article is patient education, not medical advice. The interpretation of borderline Wilson disease test results depends heavily on your full clinical picture. A hepatologist or metabolic liver disease specialist is best positioned to apply the Leipzig score to your specific case and recommend the next test.

References


  1. Schilsky, Michael L., Eve A. Roberts, Jeff M. Bronstein, et al. “A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases.” Hepatology 82, no. 3 (2022): E41–E90. https://doi.org/10.1002/hep.32801. 

  2. Mak, Chloe M., Ching-Wan Lam, and Sidney Tam. “Diagnostic Accuracy of Serum Ceruloplasmin in Wilson Disease: Determination of Sensitivity and Specificity by ROC Curve Analysis among ATP7B-Genotyped Subjects.” Clinical Chemistry 54, no. 8 (2008): 1356–1362. https://doi.org/10.1373/clinchem.2008.103432. 

  3. Demirkiran, Meltem, Joseph Jankovic, Richard Alan Lewis, and Diane W. Cox. “Neurologic presentation of Wilson disease without Kayser-Fleischer rings.” Neurology 46, no. 4 (1996): 1040–1043. https://doi.org/10.1212/wnl.46.4.1040. 

  4. European Association for the Study of the Liver. “EASL Clinical Practice Guidelines: Wilson’s disease.” Journal of Hepatology 56, no. 3 (2012): 671–685. https://doi.org/10.1016/j.jhep.2011.11.007. 

  5. Nicastro, Emanuele, Giusy Ranucci, Pietro Vajro, Angela Vegnente, and Raffaele Iorio. “Re-evaluation of the Diagnostic Criteria for Wilson Disease in Children With Mild Liver Disease.” Hepatology 52, no. 6 (2010): 1948–1956. https://doi.org/10.1002/hep.23910. 

  6. Alkhouri, Naim, Regino P. Gonzalez-Peralt, and Valentina Medici. “Wilson disease: a summary of the updated AASLD Practice Guidance.” Hepatology Communications 7, no. 6 (2023). https://doi.org/10.1097/HC9.0000000000000150. 

  7. Xuan, Andy, Ian Bookman, Diane W. Cox, and Jenny Heathcote. “Three atypical cases of Wilson disease: Assessment of the Leipzig scoring system in making a diagnosis.” Journal of Hepatology 47, no. 3 (2007): 428–433. https://doi.org/10.1016/j.jhep.2007.05.016. 

  8. Czlonkowska, Anna, Michael Litwin, Piotr Chabik, et al. “Wilson disease.” Nature Reviews Disease Primers 4, no. 1 (2018): 22. https://doi.org/10.1038/s41572-018-0024-5. 

Dies ist Patientenaufklärung, keine medizinische Beratung. Besprich Entscheidungen zu deiner Behandlung immer mit deinem eigenen medizinischen Team.